Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and PK of Inhaled Esketamine in Healthy Volunteers
NCT03407872Phase 1Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Celon Pharma S.A. Primary endpoints: Maximum Esketamine Plasma Concentration up to 24 hours, Area Under the Curve 0-24h and 1 more. Started Dec 2017; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03407872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407872.